| All Releases |
|---|
 |
The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance
07-23-2008
|
22.9 KB
|
| |
PARSIPPANY, N.J., Jul 23, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter and first half of 2008.
Financial highlights for the second quarter of 2008:
-- Net revenue increased by 54% to $86.7 million for the second quarter of 2008 from $56.4 million for the second qua...
|
|
|
New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery
07-14-2008
|
10.5 KB
|
| |
PARSIPPANY, N.J., Jul 14, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that the results of ESCAPE -2, a pivotal Phase 3 efficacy trial of its investigational agent Cleviprex(TM) (clevidipine butyrate) injectable emulsion, were published in the July issue of the journal Anesthesia and Analgesia. The clinical trial dem...
|
|
|
The Medicines Company to Announce Second Quarter 2008 Financial Results on Wednesday, July 23, 2008
07-09-2008
|
7.4 KB
|
| |
PARSIPPANY, N.J., Jul 09, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 23, 2008 at 8:30 a.m. Eastern Time to discuss second quarter 2008 financial results, guidance and operational developments.
The conference call will be available via phone and webcast. The dial i...
|
|
|
Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
06-20-2008
|
11.4 KB
|
| |
VANCOUVER, British Columbia, Jun 20, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex(TM) (clevidipine butyrate) injectable emulsion to control blood pressure during cardiac surgery may be associated with a reduced risk of heart attack...
|
|
|
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations
06-17-2008
|
9.1 KB
|
| |
PARSIPPANY, N.J., Jun 17, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that Glyn R. Parkin has joined the Company as Senior Vice President, International Operations. Working with other senior leaders of the Company, Parkin will be responsible for the design, implementation and leadership of the international organiza...
|
|
|
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
06-05-2008
|
7.0 KB
|
| |
PARSIPPANY, N.J., Jun 05, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) is scheduled to present at The Seventh Annual Needham Biotechnology and Medical Technology Conference on June 12th, at 3:00pm Eastern Time. A company overview and outlook will be provided in the presentation.
The session will be webcast with a link available ...
|
|
|
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350
06-03-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., Jun 03, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to three executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S.
...
|
|
|
Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis from VELOCITY Trial
05-29-2008
|
10.8 KB
|
| |
WASHINGTON, May 29, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that its investigational agent, Cleviprex(TM) (clevidipine butyrate) injectable emulsion was well tolerated in elderly patients and rapidly achieved and maintained blood pressure control in patients presenting to the emergency department or intensive ca...
|
|
|
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
05-28-2008
|
10.7 KB
|
| |
PARSIPPANY, N.J., May 28, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax(R) (bivalirudin) in the treatment of acute coronary syndromes (ACS) initiated...
|
|
|
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
05-22-2008
|
15.6 KB
|
| |
PARSIPPANY, N.J., May 22, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that the New England Journal of Medicine published results from the HORIZONS-AMI trial. According to findings, Angiomax(R) (bivalirudin) significantly improved net clinical adverse events by 24 percent as well as resulted in a reduction in overall...
|
|
|
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350
05-15-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., May 15, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to four executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S.
...
|
|
|
Results Published in JACC Show Clinical Advantage of Switching to Angiomax from Heparin in Acute Coronary Syndrome Patients Undergoing Early Invasive Treatment
05-05-2008
|
12.5 KB
|
| |
PARSIPPANY, N.J., May 05, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced that the Journal of the American College of Cardiology published a new subgroup analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrating that switching to Angiomax(R) (bivalirudin) after pre-trea...
|
|
|
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350
04-30-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., Apr 30, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to two executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S.
...
|
|
|
The Medicines Company Reports First Quarter 2008 Financial Results
04-23-2008
|
16.3 KB
|
| |
PARSIPPANY, N.J., Apr 23, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008.
Financial highlights for the first quarter of 2008:
-- Net revenue increased by 19% to $79.4 million for the first
quarter of 2008 from $66.6 million for the first quarter ...
|
|
|
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350
04-15-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., Apr 15, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to fourteen executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S....
|
|
|
The Medicines Company to Announce First Quarter 2008 Financial Results on Wednesday, April 23, 2008
04-09-2008
|
7.4 KB
|
| |
PARSIPPANY, N.J., Apr 09, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 23, 2008 at 8:30 a.m. Eastern Time to discuss first quarter 2008 financial results and operational developments.
The conference call will be available via phone and webcast. The dial in informat...
|
|
|
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
03-29-2008
|
15.5 KB
|
| |
CHICAGO, Mar 29, 2008 (BUSINESS WIRE) -- The Medicines Company (Nasdaq: MDCO) today announced that Angiomax(R) (bivalirudin) resulted in improved net adverse clinical outcomes and reduced the risk of major bleeding despite the sex, age, diabetes status or renal function of heart attack patients in the HORIZONS-AMI trial compared to a more complex t...
|
|
|
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350
03-14-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., Mar 14, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to four executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S.
...
|
|
|
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350
02-15-2008
|
8.0 KB
|
| |
PARSIPPANY, N.J., Feb 15, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to sixteen executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. ...
|
|
|
The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results
02-13-2008
|
23.0 KB
|
| |
PARSIPPANY, N.J., Feb 13, 2008 (BUSINESS WIRE) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the full year and fourth quarter of 2007.
Financial highlights for the full year of 2007:
-- Net revenue increased by 20% to $257.5 million for 2007 from $214.0 million for 2006.
-- Angiomax(R) (bivali...
|
|
|
